Fund
Syncona
Syncona followed on in the round of OMass Therapeutics (310 M$, Series C) on 15 October 2026. It is the only health round Bolus has logged for it so far.
Page built from the operations logged, not from a written profile. It says nothing about the fund's activity outside the scope of Bolus, which is health venture capital in Europe and the United States.
Get Syncona's next deals
An email each time this fund appears in a new health deal, plus the Friday newsletter. Nothing else.
Free. One click to unsubscribe. The list is never sold. In French.
- Operations logged
- 1
- Lead
- 0
- New entries
- 0
- Follow ons
- 1
- Latest operation
- 15 October 2026
- Sectors
- Biotech
Operations
| Date | Company | Stage | Amount | Role |
|---|---|---|---|---|
| 15 Oct | United Kingdom, Biotech | Series C | 310 M$ | Existing investor |
Co investors 12 funds crossed
- Bain Capital Life Sciences 1 operation
- British Business Bank 1 operation
- Forbion 1 operation
- GV 1 operation
- Janus Henderson Investors 1 operation
- Jefferson Life Sciences 1 operation
- Northpond Ventures 1 operation
- Novo Holdings 1 operation
- Oxford Science Enterprises 1 operation
- Sanofi Ventures 1 operation
- SV Health Investors 1 operation
- University of Oxford 1 operation
Funds that appeared in the same rounds, in any capacity. Geographies logged: United Kingdom.